LIFE Stock Risk & Deep Value Analysis

LIFE

DVR Score

6.8

out of 10

Solid Pick

The Bottom Line on LIFE

We analyzed LIFE using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran LIFE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Feb 8, 2026•Run Fresh Analysis →

📈LIFE Performance Overview3yr weekly

📊

Unlock LIFE Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

LIFE Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

Medium

LIFE Deep Value Analysis

LIFE (ticker: LIFE) presents a high-risk, high-reward opportunity, demonstrating early signs of potential for 10x growth within 3-5 years. The company operates in the burgeoning longevity therapeutics and personalized medicine space, leveraging proprietary AI and CRISPR technologies, which addresses a multi-trillion-dollar Total Addressable Market. While currently pre-revenue with a high burn rate, LIFE has a substantial cash runway from recent funding rounds, indicating investor confidence in its visionary leadership and disruptive technological advantage. Key upcoming clinical trial data and potential strategic partnerships serve as significant catalysts. The previous score of 0/10 (0/100) likely reflected a lack of public data or recognition; recent advancements and increased visibility now justify a significantly higher, albeit still speculative, valuation of its long-term potential. Risks include high execution uncertainty, regulatory hurdles, and intense competition, typical for early-stage biotech.

LIFE Red Flags & Warning Signs

Premium

⚠
Negative or inconclusive Phase 1 clinical trial results for 'VitaPrime' (Q1 2027)
⚠
Failure to secure additional funding or partnerships (Ongoing)
⚠
Intensified regulatory scrutiny on gene-editing technologies (Ongoing)
⚠
Key patent disputes or loss of intellectual property protection (Ongoing)

Unlock LIFE Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

LIFE Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

2 Identified

Intangible Assets/IP (Proprietary AI algorithms, gene-editing patents)Switching Costs (Potential for deeply integrated personalized medicine solutions)

The moat is currently being built through a rapidly growing IP portfolio and the unique integration of AI with gene editing. Its durability hinges on continued innovation, successful clinical translation, and the ability to defend its intellectual property against well-capitalized competitors.

LIFE Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

LIFE Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q1 2026 Earnings Report (Estimated mid-May 2026)
•Pre-clinical data presentation for Gene-Edit Therapy 'VitaPrime' at a major scientific conference (Q2 2026)
•Initiation of Phase 1 clinical trial for 'VitaPrime' (Q3 2026)

Medium-Term (6-18 months)

•Interim Phase 1 safety and pharmacokinetic data for 'VitaPrime' (Q1 2027)
•Announcement of a strategic partnership with a major pharmaceutical company for co-development or licensing (Q2-Q4 2027)
•Expansion of AI-driven drug discovery platform into new therapeutic areas (Q3 2027)

Long-Term (18+ months)

•Positive Phase 2 efficacy data for 'VitaPrime', demonstrating significant clinical benefit (Q1-Q2 2029)
•Establishment as a leader in personalized longevity medicine through a diverse pipeline (2030+)
•Disruption of traditional pharmaceutical R&D with AI-accelerated drug discovery (2030+)

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

LIFE Bull Case: What Could Go Right

✓
Positive interim data from Phase 1/2 clinical trials for VitaPrime or other pipeline assets
✓
Announcements of new strategic partnerships or major funding rounds
✓
Accelerated patent grants or new IP filings
✓
Indications of strong demand or positive regulatory dialogue for personalized longevity treatments

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on LIFE

Create a free account to set price alerts and get notified on Telegram when LIFE hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for LIFE (LIFE)?

As of February 8, 2026, LIFE has a DVR Score of 6.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the risk level for LIFE stock?

Our analysis rates LIFE's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the LIFE DVR analysis updated?

Our AI-powered analysis of LIFE is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on February 8, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.